Chugai Pharmaceutical, a Roche subsidiary, has partnered with Singapore-based AI company Gero to identify drug targets for age-related diseases using Gero’s human data-centric platform. The collaboration aims to generate novel antibody drug candidates leveraging Chugai’s engineering technologies and could potentially unlock new therapies for aging-related conditions. Chugai has secured exclusive rights with milestone and royalty provisions tied to commercialization.